To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Edison Pharmaceuticals Closes $20M Series F Financing
Edison Pharmaceuticals, Inc. announced today that it has closed a Series F Preferred Financing, raising $20M. Mitsui & Co. Global Investment, Inc. led the financing and will occupy a board of directors seat.
Proceeds will be used to advance the clinical development of EPI-743. The company has recently announced the initiation of phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh syndrome and Friedreich's ataxia. Additional clinical development initiatives are underway and will be announced in Q1 2013.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
